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Background: To investigate the potential dosimetric and clinical benefits of Deep Inspiration Breath-Hold (DIBH)
technique during radiotherapy of breast cancer compared with Free Breathing (FB).
Methods: Eight left-sided breast cancer patients underwent a supervised breath hold during treatment. For each
patient, two CT scans were acquired with and without breath hold, and virtual simulation was performed for
conventional tangential fields, utilizing 6 or 15 MV photon fields. The resulting dose–volume histograms were
calculated, and the volumes of heart/lung irradiated to given doses were assessed. The left anterior descending
coronary artery (LAD) mean and maximum doses were calculated, together with tumour control probability (TCP)
and normal tissue complication probabilities (NTCP) for lung and heart.
Results: For all patients a reduction of at least 16% in lung mean dose and at least 20% in irradiated pulmonary
volumes was observed when DIBH was applied. Heart and LAD maximum doses were decreased by more than
78% with DIBH. The NTCP values for pneumonitis and long term cardiac mortality were also reduced by about 11%
with DIBH. The NTCP values for pericarditis were zero for both DIBH and FB.
Conclusion: Delivering radiation in DIBH conditions the dose to the surrounding normal structures could be reduced,
in particular heart, LAD and lung, due to increased distance between target and heart, and to reduced lung density.
Keywords: Deep inspiration breath-hold gating radiotherapy, Breast cancer radiotherapy, NTCP, TCPBackground
With advances in mammography, breast cancer is being
detected at an earlier stage and is therefore more curable
[1]. The management of early breast cancer with conser-
vative surgery and adjuvant whole radiotherapy is now a
widely established alternative to mastectomy, which has
long been the only accepted form of treatment [2]. Whole
breast radiotherapy classically utilizes tangential fiels to
encompass the entire breast volume and (tipically) wedge
compensation are also used to ensure (a more oppure the
better) homogeneous dose distribution. However, recent
studies have shown that intrafraction target motion can
decrease dose homogeneity [3-7] which is believed to be* Correspondence: bruzzaniti@ifo.it
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reproduction in any medium, provided the orone of the main contributing factors to poor cosmesis and
possibly to decreased tumor control [8].
The main cause of radiation underdosage in breast can-
cer patients can be attributed to the target motion due to
respiration [2]. Breathing adapted radiotherapy of breast
cancer seems to provide reduced radiation doses to
Organs At Risk (OARs) without compromising Clinical
Target Volume (CTV) coverage. Irradiation techniques
have been developed to reduce the effects of motion,
which can result in better dose homogeneity [2]. These
techniques implies that the radiation beam is turned on
only during a pre-specified phase or amplitude of the re-
spiratory cycle, thus modifying target position and lung
density within the field aperture. Several studies have re-
ported that an appreciable reduction in cardiac volume
within tangential radiation portals for left-sided breast
cancer can be achieved by deep inspiration, either by aral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[11] voluntary breath-hold, or by a complex technique of
spirometrically monitored and forced breath-hold [12,13].
Additionally, they have also reported on pulmonary tissue
sparing for both left- and right-sided cancers [11,13].
However, problems with breath-hold level reproducibil-
ity and verification, as well as with patient cooperation
may limit the feasibility of this approach. Thus, the opti-
mal parameters for the use of breathing control for breast
cancer have not been established yet.
Korreman et al. [14] have investigated the possibility
of decreasing chest wall excursion during breath-hold by
audio-visually coaching the patient to a reproducible
breath-hold level. The use of coaching appears to have
the advantage of minimizing inter-session variability,
and Kini et al. [15] have shown that such procedures
may well allow a reduction of margins, implying even
better normal tissue sparing.
A study by Stranzi and Zurl [16] demonstrates that
during Deep Inspiration Breath-Hold (DIBH) technique,
the left-sided breast and heart were separated during
radiation treatment, thus excluding substantial heart
volumes from the high-dose area.
The main objective of this study is to evaluate radio-
biological, dosimetric effects and benefits of the DIBH
technique during whole breast radiotherapy.
Methods
Eight patients with left-early breast cancer who underwent
conservative surgery and with a prescription of whole
breast adjuvant radiotherapy were considered in this
study. Patient eligibility criteria were: ≥ 18 years of age;
not oxygen dependent; did not experience pain while in
the supine position. Patient age ranged from 39 to 70 years
(mean 51 years).
Training
The training session established the patient’s inspiration
level for treatment and breath-hold duration. A reflect-
ive marker (RPM Box) was placed on the patient’s ab-
dominal surface, midway between the xyphoid process
and the umbilicus to monitor the respiratory motion.
The patients were asked to breathe freely and then in-
hale and hold their breath at a comfortable level, just
below their maximum inspiration capacity, for at least
15 seconds. This cycle was to be repeated two or three
times in succession. The respiratory signal was recorded
with the Varian RPM™ system. Once a comfortable deep
inspiration level was found, a lower and an upper
thresholds were placed on the respiratory signal to de-
fine the gating window. The training was carried out by
providing the patient with electronic eyeglasses (video
coaching) which allowed visualization of a coloured
band, representing the gating window, and a movablebar that followed the patient’s abdomen/chest move-
ment, thus ensuring the reproducibility of deep inspir-
ation amplitude. The width of the gating window was
chosen such that the allowed amplitude of the residual
RPM box motion was 0.5 cm. Under these conditions, a
CT scan was performed for treatment planning. The
patient had to be able to understand these instructions,
be capable of performing a reproducible breath-hold,
and be able to maintain it for at least 15 seconds. The
training session required about 30 minutes.
CT investigations
A CT Scanner Lightspeed 16 slices (GE) was used. The
patients were placed in the treatment position supine
with their arms raised above their head, the sternum in
horizontal position and their shoulders, elbows and back
immobilised with a wingboard. Orthogonal room lasers
were used to place skin markers to verify that no shift
occurred between scans. Finally, the RPM box was
placed between the xyphoid process and the umbilicus,
i.e. in proximity to the target breast, but outside the area
to be covered by the radiation treatment fields. Two
spiral scans were acquired, each covering the area from
the mid-neck to the upper abdomen. The scanning pa-
rameters were: 120 kVp, mA range = 30–150 mA, 0.8 s/
rotation, beam collimation = 20 mm, distance between
two successive slices = 2.5 mm, image matrix = 512×512
pixels, field of view (FOV) = 50 cm. The first scan for con-
ventional treatment planning (reference scan) was ac-
quired during Free Breathing (FB). The second scan,
acquired during DIBH, was manually started immediately
after the inspiratory plateau was reached, as visually con-
firmed by the respiration monitoring. Both the antero-
posterior FB motion amplitude during FB, and the max-
imum DIBH amplitude, of the RPM box, as detected by
the RPM™ software, were registered for each patient.
Whenever the CT scan acquisition was longer than the pa-
tient’s breath-hold time the scan was broken into two seg-
ments This happened for only one patient. The total time
for the two CT acquistions was less than 15 minutes.
Treatment planning
3D planning and dose computations were performed
using the Anisotropic Analytical Algorithm (AAA) in
the Eclipse treatment planning system (Varian Medical
Systems, Palo Alto, USA). The planning CT scans con-
sisted of 2.5 mm spaced slices of the whole chest, ac-
quired during DIBH and FB. Structures such as body
(external contour), Planning Target Volume (PTV), ipsi-
lateral lung (IL), heart, anterior descending coronary
artery (LAD) were delineated on both FB and DIBH
reconstructed 3D-CT datasets.
Treatment plans were created using both CT data sets
according to standard protocols. Two conventional 6 MV
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some patients a mixture of 6 and 15 MV photons fields
were needed to improve target coverage. The fields were
shaped with 120 leafs multileaf collimators, and wedges
were used when appropriate for dose homogenization.
The two fractionation schedules currently in use in our
Institute [17] were adopted. The first was a conventional
treatment at 2 Gy daily fraction with a total dose of 50 Gy;
the second was an hypofractionated treatment with a
3.4 Gy daily fraction up to 34 Gy total dose.
The plans were normalized to the target mean dose for
the two breathing conditions (FB, DIBH). All targets were
treated following internal criteria on dose homogeneity:
90% to 107% of the prescription dose. For each patient the
Dose Volume Histograms (DVHs) of PTV, heart, IL and
LAD were registered. From these data the mean and max-
imum doses of the IL, heart and LAD were extracted. In
addition the percentage volume of the heart receiving more
than 20 Gy and more than 40 Gy (V20(%) and V40(%)) and
the percentage volume of the IL receiving more than 10 Gy
and more than 20 Gy (V10(%) and V20(%)) were recorded.
The central lung distance (CLD) [18], the absolute lung vol-
ume (ALV), i.e. the volume of the ipsilateral lung, the Irra-
diated Lung Volume (ILV), defined as the ipsilateral lung
volume within the 50% isodose, the normalized irradiated
lung volume (NILV) which is the ratio of ILV over ALV and
the minimum distance between the heart and the target
volume were measured on all the CT datasets.
TCP and NTCP
Assuming that cell survival in a tumor follows a binomial
statistic, the requirement of total eradication of all clono-
genic cells yields the Poisson formula for Tumor Control
Probability (TCP):
TCP ¼ e−N⋅SF ð1Þ
where N* is the initial number of clonogenic tumor cells.
The Lyman-Kutcher-Burman (LKB) probit model [19]
was used for calculating Normal Tissue Compliation
Probability (NTCP). According to this model, if a frac-
tion v of an organ is uniformly irradiated at dose D, the











where t is defined as,
t ¼ D−TD50 vð Þ
m ⋅TD50 vð Þ ð3Þ
and,
TD50 vð Þ ¼ TD50 1ð Þ ⋅ v−n ð4ÞThe parameters n and m determine the volume depend-
ence of NTCP and the slope of the curve NTCP vs. Dose,
respectively. TD50(1) is the dose that leads to a 50% com-
plication probability when it is delivered uniformly to the
whole organ [19]. To estimate TD50(1) only standard frac-
tionations of 1.8–2 Gy per day, 5 days per week, were con-
sidered [19]. As the irradiation of the organs at risk is
almost never uniform, the effective volume method [19] is










where Di is the dose delivered to the volume fraction vi,
and N is the number of bins of the differential DVH. By
Eq. (4), an inhomogeneous dose distribution is converted
to an equivalent uniform irradiation of a fraction veff of the
organ at the maximum dose Dmax.
TCP and NTCP were calculated using the isoBED
software [20] which applies formulas (2), (3), (4) and (5) to
the differential DVHs exported from the treatment
planning system. For the breast tumor radiobiological
parameters were derived for the clinical data: α = 0.13 Gy-1
and α/β = 4.6 Gy [17].
The considered endpoints for heart toxicity were peri-
carditis and long term mortality. The NTCP for pericar-
ditis was calculated using the LKB model with m = 0.13,
n = 0.64, TD50 = 50.6 Gy and an α/β ratio of 2.5 Gy
[21,22]. For long term mortality an α/β ratio of 3 Gy and
the following parameters TD50 = 52.3 Gy, n = 1 and
m = 0.28 were considered. This last value was found to
give the best approximation to the Erikson breast dose
effect curve [23] using the LKB model with TD50 and n
fixed as in Gagliardi et al. [22,24]. The NTCP for LAD
toxicity was calculated with the values n = 0.35; m = 0.1;
TD50 = 48 Gy [25]. For lung toxicity we considered pneu-
monitis as endpoint and used TD50 = 30.8 Gy, m = 0.37
and n = 0.99 with an α/β ratio of 3Gy [26].Statistical analysis
The dosimetric data of PTV, contra-lateral breast, heart
and ipsilateral lung and LAD, as well as the TCP and
NTCP values were compared between the different
breathing techniques.
Although the number of patients was very small a
standard statistical assessment of the significance of the
results was performed. Two tailed paired t-test was used
to estimate the statistical significance of the differences
between groups. A p-value less than 0.05 was considered
statistically significant.
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The standardized breath-hold procedure was easily under-
stood by the patients and the training of the breathing pat-
tern took a maximum of 30 minutes. By using eyeglasses
the breath-hold technique was well accepted with a mean
duration of 21 s (range: 15–48 s).
During the FB scans, the mean value over all patients of
the vertical (antero-posterior) motion amplitude of the
RPM box was 7 mm (range of 4 –11 mm). During DIBH
the mean of the maximum amplitudes was 17 mm (range:
8–27 mm), i.e. a relative increase of 142.9% with respect
to FB was found.
A cumulative DVH representing the typical change
between FB and DIBH in the dose distributions of the
PTV and relevant normal tissues is shown in Figure 1.Pulmonary doses
CLD did not extend beyond 2.5 cm, regardless of whether
the patient was in a FB or in a DIBH state.. No statistically
significative difference in CLD values was found between
DIBH and FB (p = 0.99).
A significant (p = 0.04) 28.7% increase in the patient av-
eraged ILV was found in DIBH with repect to FB, however
when the normalized ILV averaged over all patients was
taken into account a 23.0% decrease was found, as shown
in Table 1.
The mean (range) and p-values of IL mean dose
(Dmean) and IL volumes receiving more than 10 Gy
(V10) and 20 Gy (V20) are shown in Table 2 for FB and
DIBH for both the conventional and the hypofractio-
nated schedules.Figure 1 Cumulative DVH showing how the dose to the critical organ
continuous lines). A standard schedule of 50 Gy/2 Gy fraction is considereIn the conventional fractionation the IL mean dose was
reduced by 18.8% in DIBH. The mean values for V10 were
11.54% and 9.08% for FB and DIBH, respectively, which
amounted to a 21.3% decrease in DIBH. In the hypofrac-
tionated schedule the IL mean dose was reduced by 16.0%
in DIBH the mean values of V10 were 10.7% and 8.32%,
respectively i.e. showed a 22.2% decrease in DIBH.
The V20 values were 8.13% and 6.11% for FB and
DIBH, respectively, for the conventional schedule
(24.8% decrease in DIBH). For hypofractionaction they
were 7.65% and 5.71%, respectively (25.4% decrease in
DIBH).
Cardiac doses
The mean value over all patients of the minimum dis-
tance between the heart and the target volume was
1.43 cm (range 0.77-2.29 cm) for the FB CT datasets
and 2.62 cm (range 2.12-3.25 cm) for the DIBH datasets.
This 83.2% increase in DIBH was statistically significant
(p = .0.0001).
In Table 3 the mean (range) and p-values of Dmean
and Dmax of both heart and LAD are shown, for both
conventional and hypofractioanted schedules and for
both FB and DIBH. In addition the V20 and V40 for the
heart are reported.
As shown in the Table 3 the maximum doses to the heart
and LAD and the mean dose to the heart were significantly
lower in DIBH, (minimum 78.3% and 2.6% decrease with
respect to FB, respectively) regardless of the schedule type.
In our series the maximum dose to LAD exceeded
20 Gy in 3/8 patients in FB, while it was lower than 20 Gy
in all patients in DIBH.s is reduced between FB (thin dashed lines) and DIBH (thick
d.
Table 1 Absolute lung volume, ILV and percentage normalized ILV in FB and DIBH
Absolute lung volume (cm3) ILV (cm3) Normalized ILV (%)
Patient # DIBH FB DIBH FB DIBH FB
1 1822.47 1428.66 81.10 67.29 4.45 4.71
2 2580.95 1313.33 97.56 43.34 3.78 3.30
3 2659.73 1539.35 199.48 180.72 7.50 11.74
4 1660.88 1165.16 71.75 59.19 4.32 5.08
5 2342.99 1483.92 75.21 71.97 3.21 4.85
6 1928.90 1068.35 192.89 122.54 10.00 11.47
7 2309.26 1301.86 177.12 118.99 7.67 9.14
8 2156.90 1209.99 64.06 81.19 2.97 6.71
All Pt Average 2182.76 1313.83 119.90 93.15 5.49 7.13
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The TCP and NTCPs for lung and heart are reported in
Table 4 as mean values with ranges. TCP values were in-
creased in the hypo-fractionated schedule, as expected
from the literature [17]. The NTCPs for Lung toxicity
and long term cardiac mortality were at least 11.2%
lower for DIBH with respect to FB, but the difference
was statistically significant only for the long term cardiac
mortality in the conventional fractionation. The NTCP for
pericarditis and for LAD toxicity were 0% in all cases.
Discussions
The aim of this paper was to investigate clinical and
dosimetric benefits of DIBH gating technique. The im-
plementation of this practice allowed us to understand
the factors influencing the correctness of this irradiation
modality.
In particular, patient training is an important compo-
nent of a clinical program that uses breath-hold respira-
tory gating for treatment [27]. It allows the patient to
become familiar with the equipment and procedure, and
provides an evaluation of the patient’s ability to perform
reproducible breath-holds. In our experience the dur-
ation of the training session was reduced to 30 minutes.
Lung inflation during inspiration increases the absolute
lung volume but decreases the percentage irradiated
lung volume (Table 1). Indeed, in 7 out of 8 patients theTable 2 Ipsilateral mean lung dose and lung volumes receivin
Conventional fractionation
DIBH FB p-v
Dmean (Gy) 4.64 5.51 0.0
(3.32 – 6.11) (3.54 – 8.84)
V10 (%) 9.08 11.54 0.0
(5.52 – 15.44) (6.46 – 19.46)
V20 (%) 6.11 8.13 0.0
(3.43 – 1.06) (3.97 – 14.11)increase in ALV overcompensated the increase in ILV.
Thus the mean lung dose should decrease, however the
differences between DIBH and FB in our series showed
only a trend (p-value = 0.05). In particular V20 was statis-
tically significantly reduced in both the investigated
schedules, while the reduction of V10 using DIBH was
confirmed only in the hypofractionated schedule.
The published literature clearly indicates the need to
reduce the irradiated heart volume as much as possible,
even if there are no data from literature able to correlate
a given risk of cardiac complication with some specific
irradiated volume, such as LAD [25].
V20 and V40 for the heart were lower than 10% and
5%, respectively, which are the constraints for long term
cardiac mortality [25,28].
The advantage of DIBH is to decrease the heart volume
included in the irradiation fields, decreasing both the
mean and the maximum dose of heart in a statistically
significant way.
The difference in LAD maximum dose between DIBH
and FB was statistically significant, while no statistically
significant difference was found in the mean dose. Since
the dose gradient is very steep on the internal side of
the photon field, the increase of the distance between
the target and the heart is very effective at decreasing
the LAD maximum dose. On the other hand the lower
doses which contribute to the mean dose are lessg more than 10 Gy (V10) and 20 Gy (V20)
Hypofractionation
alue DIBH FB p-value
505 3.15 3.75 0.0505
(2.25 – 4.16) (2.40 – 6.01)
520 8.32 10.70 0.0405
(4.93 – 14.22) (5.79 – 17.92)
398 5.71 7.65 0.0406
(3.14 – 10.52) (3.62 – 13.41)
Table 3 The mean (range) and p-values for Dmean, Dmax of both heart and LAD
Conventional fractionation Hypofractionation
Organ Parameter DIBH FB p-value DIBH FB p-value
Heart
Dmax (Gy)(*) 5.00 29.19 0.0015 3.85 24.75 0.0025
(2.00 – 10.00) (5.00 – 52.00) (1.00 – 8.00) (3.00 – 46.00)
Dmean (Gy) 1.24 1.68 0.0106 0.84 1.14 0.0106
(1.03 – 1.43) (1.29 – 2.48) (0.70 – 0.97) (0.87 – 1.68)
V20
(**) (%) 0.00 0.39 0.1574 0.00 0.33 0.1644
(0.00 -0.00) (0.00 -1.61) (0.00-0.00) (0.00 – 1.40)
V40
(**) (%) 0.00 0.16 0.1719 0.00 0.07 0.1708
(0.00 -0.00) (0.00 – 0.70) (0.00-0.00) (0.00 -3.00)
LAD
Dmax (Gy)(*) 4.25 19.62 0.0488 3.10 16.75 0.0479
(2.00 – 11.00) (3.00 – 52.00) (1.00 – 8.00) (2.00 – 46.00)
Dmean (Gy) 2.74 9.01 0.0914 1.86 6.12 0.9140
(0.80 – 7.55) (1.45 – 28.05) (0.54 – 5.13) (0.99 - 19.07)
(*)EQD2 values using α/β =2.5 Gy for Pericardites in heart an for LAD.
(**)EQD2 values using α/β =3.0 Gy for long term Mortality.
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received by any part of the LAD should be lower than
20 Gy, according to Aznar et al. [25]. TCP calculation of
both techniques revealed, as expected, a similar tumor
control. When the NTCP models were applied, the dif-
ference observed for long term mortality was statisti-
cally significant only for the conventional fractionation.
For the pericarditis endpoint, no differences were ob-
served in both fractionation schedules. These results
need to be confirmed because the small number of pa-
tients does not allow a statistic strong enough to state
definitive conclusions. In addition the parameters of the
NTCP/TCP models are generally derived using values
from the literature which were derived using “static” or
“averaged on respiratory cycle” CT images. Besides a
careful follow up of the clinical outcome of these pa-
tients and the addition of more patients to the study,
the investigation of lung density related parameters
could further elucidate the dosimetric benefits of DIBH
gating technique.Table 4 TCP and NTCP for FB and DIBH
Conventional fraction
Parameter DIBH FB
TCP (%) 96.40 96.30
(92.5 – 98.23) (94.33 – 97.36)
Heart NTCP (%) [pericarditis] 0.00 0.00
(0.00 – 0.00) (0.00 – 0.00)
Heart NTCP (%) [long term mortality] 0.71 0.80
(0.69 – 0.74) (0.72 – 0.99)
Lung NTCP (%) [pneumonitis] 6.58 11.48
(0.23 – 13.18) (0.77 – 33.54)Conclusion
In summary, radiation delivery in inspiration breath-
hold conditions can reduce the dose delivery to the sur-
rounding normal structures, in particular cardiac doses,
due to the increase of the distance between target and
heart as shown by our data and also confirmed by other
authors [16]. As a result a consistent reduction in
NTCP is achieved, with no loss in tumour control.
Moreover our results suggest that DIBH, with proper
patient selection and training, is a practical and achiev-
able solution for minimizing respiratory-induced target
motion during both simulation and treatment. On the
negative side the use of gating techniques with breath-
hold increases treatment room occupation due to a
more complex set-up. Treatment time is also increased
when multiple breath-holds and consequent breathing
recovery intervals are needed to complete the irradi-
ation of a beam. However this latter side effect could be
compensated by decreasing the beam-on time with an
increase in the dose rate.ation Hypofractionation
p-value DIBH FB p-value
0.3604 99.99 100.00 0.3506
(99.97 – 100) (100.00- 100.00)
———— 0.00 0.00 ————
(0.00 – 0.00) (0.00 – 0.00)
0.0385 0.72 0.87 0.0667
(0.69 – 0.75) (0.73 – 1.22)
0.2212 16.71 29.26 0.1618
(8.19 – 29.43) (9.57 – 97.70)
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